Oncology And Biologic Therapies Will Unlock Global Opportunities

Published
25 Mar 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$21.89
33.4% undervalued intrinsic discount
14 Aug
US$14.57
Loading
1Y
26.3%
7D
3.7%

Author's Valuation

US$21.9

33.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 16%

Shared on24 Apr 25
Fair value Increased 20%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 17%

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 20%

AnalystConsensusTarget has increased revenue growth from 12.4% to 16.9%, increased profit margin from 10.5% to 19.3%, decreased future PE multiple from 120.8x to 71.9x and increased shares outstanding growth rate from -0.0% to -0.0%.